StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.
Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.
View Our Latest Stock Report on VNRX
VolitionRx Stock Down 6.4 %
VolitionRx (NYSE:VNRX – Get Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. Sell-side analysts expect that VolitionRx will post -0.34 EPS for the current fiscal year.
Hedge Funds Weigh In On VolitionRx
A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of VolitionRx Limited (NYSE:VNRX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.09% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
- Five stocks we like better than VolitionRx
- How to buy stock: A step-by-step guide for beginnersÂ
- Autodesk’s Quarterly Results Could Drive It Back to Recent Highs
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- A Bubble is Brewing in Oracle Stock, and it’s Only Getting Bigger
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Danaos Benefits from Increasing Demand in Container Shipping
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.